ERR2598151
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 19
- umap1_2d
- -4.019449222
- umap2_2d
- 1.257645829
- umap1_3d
- -1.674417633
- umap2_3d
- 1.880275271
- umap3_3d
- -2.382896497
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.350
- WNT_BETA_CATENIN_SIGNALING+0.290
- INTERFERON_ALPHA_RESPONSE+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- COAGULATION+0.160
- NOTCH_SIGNALING+0.160
- APICAL_SURFACE+0.140
- HEDGEHOG_SIGNALING+0.140
- KRAS_SIGNALING_UP+0.140
- KRAS_SIGNALING_DN+0.110
Top 10 suppressed
- PROTEIN_SECRETION-0.530
- OXIDATIVE_PHOSPHORYLATION-0.500
- MTORC1_SIGNALING-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.340
- GLYCOLYSIS-0.280
- MYC_TARGETS_V1-0.270
- PI3K_AKT_MTOR_SIGNALING-0.270
- ADIPOGENESIS-0.240
- ANDROGEN_RESPONSE-0.240
- MITOTIC_SPINDLE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3W6-01A-12R-A22K-07 | — | A | 0.779 |
| 2 | SRR1489155 | GTEX | — | 0.779 |
| 3 | 20040065.TNBC | — | D | 0.770 |
| 4 | SRR1354577 | GTEX | — | 0.770 |
| 5 | SRR1429957 | GTEX | — | 0.770 |
| 6 | SRR1456333 | GTEX | — | 0.769 |
| 7 | SRR2774280 | — | — | 0.768 |
| 8 | BS_JT82QGXF | Med | Medulloblastoma | 0.767 |
| 9 | TCGA-CF-A47V-01A-11R-A23W-07 | — | — | 0.766 |
| 10 | SRR1436966 | GTEX | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.040 | Idelalisib | — uncovered |